rss
Br J Ophthalmol 2004;88:199-203 doi:10.1136/bjo.2003.018234
  • Clinical science
    • Scientific reports

A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension

  1. M Diestelhorst1,
  2. L-I Larsson2,*,
  3. for The European Latanoprost Fixed Combination Study Group
  1. 1Department of Ophthalmology, University of Cologne, Cologne, Germany
  2. 2Pharmacia Corporation, Sweden
  1. Correspondence to: Dr M Diestelhorst Department of Ophthalmology, Univerisitäts-Augenklinik, University of Köln, Joseph-Stelzmann-Strasse 9, Köln 50931, Germany; michael.diestelhorstmedizin.uni-koeln.de
  • Accepted 25 June 2003

Abstract

Background: To compare the intraocular pressure (IOP) lowering effect and safety of the fixed combination of latanoprost and timolol with that of the concomitant use of the individual components.

Methods: A 12 week, double masked, randomised, crossover, multicentre study of patients with open angle glaucoma or ocular hypertension and IOP controlled on ocular hypotensive treatment (mean ≤21 mmHg). Patients received either a once daily morning dose of the fixed combination of latanoprost 0.005% and timolol 0.5% or once daily evening latanoprost 0.005% and twice daily timolol 0.5% for six weeks and then switched to the other combination. The primary efficacy endpoint was the within-patient difference in diurnal IOP between fixed and unfixed treatment combinations after six weeks of treatment; a one sided 97.5% confidence interval (CI) for the mean difference in IOP <1.0 mmHg indicated the fixed combination was not inferior to the unfixed combination. Adverse events were recorded at each visit.

Results: In all, 190 patients were included in observed cases analyses (93 fixed to unfixed combination; 97 unfixed to fixed combination). Mean IOP at baseline was 16.9 mmHg in both groups. The mean diurnal IOP was 17.0 mmHg after fixed combination treatment and 15.9 mmHg after unfixed combination therapy (p<0.0001). The difference in mean within-patient diurnal IOP was 1.1 mmHg favouring the unfixed combination (95% CI 0.8 to 1.4 mmHg). Both treatments were tolerated well.

Conclusions: Although the primary efficacy endpoint was not met, once daily administration of the fixed combination of latanoprost and timolol was found to be safe and effective. The fixed combination provides a convenient alternative to the three instillations required with the individual components.

Footnotes

  • ↵* Dr Larsson was with the Department of Ophthalmology, Uppsala University Hospital, Uppsala, Sweden, at the time the research was conducted.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.